今日，轩竹生物（02575.HK）正式港股上市，开盘涨超153%。对于任何一家创新药企来说，从研发迈向商业化，就如同穿越一条布满荆棘的狭窄通道。轩竹生物作为背靠四环医药的“创二代”，其港股IPO无疑成为市场焦点。然而，拨开资本市场的喧嚣，我们看到的不仅是一颗冉冉升起的新星，更是一个在激烈产业变革中奋力突围的样本。01转战港股公开资料显示，轩竹生物是一家以创新为驱动的中国生物制药企业，分拆自四环医药...
Source Link今日，轩竹生物（02575.HK）正式港股上市，开盘涨超153%。对于任何一家创新药企来说，从研发迈向商业化，就如同穿越一条布满荆棘的狭窄通道。轩竹生物作为背靠四环医药的“创二代”，其港股IPO无疑成为市场焦点。然而，拨开资本市场的喧嚣，我们看到的不仅是一颗冉冉升起的新星，更是一个在激烈产业变革中奋力突围的样本。01转战港股公开资料显示，轩竹生物是一家以创新为驱动的中国生物制药企业，分拆自四环医药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.